Diego A. Díaz-García, Medical Oncologist, CEO, and Founder of CánCare – Advanced Oncology Specialty, shared a post on X about a paper by Martin Wermke et al. published in the Journal of Clinical Oncology:
“DLL3/CD3 T-cell engager obrixtamig (BI 764532) in SCLC and neuroendocrine carcinomas (ph I):
- n=168, heavily pretreated (72% ≥2L, 51% prior PD-1/L1)
- ORR: 23% overall; B2/B3 regimens ≥90 mg/kg: ORR 28%
- SCLC 21%
- epNEC 27%
- LCNEC-L 70%
- Median DoR: 8.5 mo (6-mo DoR rate 70%)
- CRS: 57% any grade, 3% ≥G3, early/reversible.”
Title: Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas
Authors: Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, Enriqueta Felip, Miguel F. Sanmamed, Olatunji B. Alese, Cyrus M. Sayehli, Edurne Arriola, Jürgen Wolf, Liza C. Villaruz, Julia Bertulis, Matus Studeny, Mohamed Bouzaggou, Xiaoyan Fang, Daniel Morgensztern
You can read the Full Article on the Journal of Clinical Oncology.
More posts featuring Diego A. Díaz-García.
